Viewing StudyNCT03051256



Ignite Creation Date: 2024-05-06 @ 9:42 AM
Last Modification Date: 2024-10-26 @ 12:18 PM
Study NCT ID: NCT03051256
Status: COMPLETED
Last Update Posted: 2023-11-01
First Post: 2017-02-03

Brief Title: Safety Tolerability PK Profile and Symptom Response of a 7-Day Dosing With 25 mg or 50 mg Daily of REL-1017 in MDD
Sponsor: Relmada Therapeutics Inc
Organization: Relmada Therapeutics Inc

Conditions & Keywords Data

Conditions:
Name
Depressive Disorder Treatment-Resistant
Depressive Disorder Major
Keywords:
Name View
REL-1017 View
d-Methadone View
Methadone View
Depression View
Refractory Depression View
Antidepressant View
Adjunctive Treatment View
NMDA Receptor Antagonist View
Excitatory Amino Acid Antagonist View
Glutamate Antagonist View